Clinical trial begins for three new HIV vaccines developed by Moderna
Three potential HIV vaccines developed by Moderna have entered clinical trials, the National Institutes of Health (NIH) has confirmed.
Phase 1 will evaluate the experimental vaccines with up to 108 HIV-negative human volunteers aged 18 to 55. The trial, called HVTN 302, will be conducted by the HIV Vaccine Trials Network (HVTN) and each participant will receive three doses of one of the vaccines.
Taking place across 11 sites in the US, those involved will be split into three groups to test the safety effectiveness of each one.
The experimental vaccines are based on messenger RNA (mRNA) technology, which was also used in Moderna’s highly effective COVID-19 vaccine, and helps the body make proteins that trigger immune responses. “Finding an HIV vaccine has proven to be a daunting scientific challenge,” explained Anthony S.
